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Compliance with prescribed asthma medication is commonly estimated from tablet counts for oral medications and
canister weights for inhaled medications. Recently, electronic medication monitoring devices, developed to evaluate
numerical compliance as well as drug use patterns, were used to assess compliance with inhaled steroids and b2-
agonists. This was the first study to electronically assess compliance with an oral asthma medication. Fifty-seven
asthmatic patients, stable on inhaled b2-agonists only with a mean FEV1 of 77% predicted ( 13%, SD) began 12
weeks of treatment with zafirlukast 20 mg twice daily. The monitoring device, an electronic TrackCapTM, recorded
the date and time on each occasion that patients removed and replaced their medication bottle caps. Patients were
told that compliance would be assessed as part of the study, but patients were not told about the specifics of the
TrackCapTM. Compliance was defined: 1. as the number of TrackCapTM events per number of prescribed tablets; and
2. as the dierence between number of tablets dispensed and number returned per number prescribed. Adherence
was defined as the number of days with two TrackCapTM events at least 8 h apart per the total number of days’
dosing. Forty-seven patients completed the study with a median compliance of 89% (mean, 80%) and a median
adherence of 71% (mean, 64%) as measured by TrackCapTM events. Compliance as estimated from return-tablet
count was slightly higher (median, 92%). High rates of compliance were maintained throughout the trial. These
results show that compliance with and adherence to a treatment of an oral, twice-daily, maintenance asthma
medication, such as zafirlukast, is high.
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Patient compliance with prescribed treatments for chronic
diseases, such as asthma, is an essential aspect of disease
management. Yet studies have shown that only one third of
all patients and 0 to less than 50% of asthma patients take
their medications as prescribed (1–7). In patients with
asthma, treatment non-compliance is thought to play a
major role in the unacceptably high morbidity and
mortality associated with the disease (8–11). To what
extent non-compliance is associated with a lack of disease
comprehension or with diculty in using medication
dispensing devices is unclear; however, both appear to
aect a patient’s inclination to either adhere to or disregardReceived 17 January 2000 and accepted in revised from 25
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0954-6111/00/090852+07 $35?00/0treatment advice. In fact, compliance with asthma medica-
tions is related to several factors including: patient under-
standing of treatment rationale; simplicity of the treatment
regimen; medication eectiveness and ease of use; social
support; and a good physician–patient relationship (1,3,
12). In adolescents, who are particularly non-compliant,
compliance is more likely to be enhanced when treatment
plans additionally address steroid phobias, peer pressure,
smoking, and other lifestyle issues (13).
However defined, compliance is dicult to measure.
Doing so, however, is a critical step in evaluating whether
or not strategies aimed at improving asthma medication
compliance are succeeding. Currently, both direct and
indirect methods are used (14). Direct measures include
assay of blood, urine, or saliva to confirm drug use and
direct observation to confirm that dispensing devices or
metered-dose inhalers (MDIs) are properly used. The value
of these objective assessments is oset by several dis-
advantages (14). The assay approach is limited by the small
number of assays available for asthma medications and by
the invasiveness of tissue sampling. Direct observations
generally occur only at clinic visits and, although patients
may demonstrate adequate skills with MDIs while under# 2000 HARCOURT PUBLISHERS LTD
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all environments. Neither approach provides information
regarding the pattern of drug use (14).
Indirect measures include clinical judgement, self-re-
ported asthma diaries and medication measurements (tablet
counts, canister weights, etc). These methods tend to
overestimate compliance and only infer drug use with
varying degrees of reliability depending on the individuals
involved. The introduction of electronic monitors that
objectively record dates and times of bottle openings or
MDI actuations—known as medication-use events—pro-
vides an advantage over other indirect methods because
researchers now can study patterns of drug use (14).
Noteworthy among the compliance literature is the
finding that patients with asthma tend to be more
compliant with their oral asthma medication (e.g., theo-
phylline) than with their inhaled asthma medication (e.g.,
corticosteroids and cromolyn sodium) (12). Oral leuko-
triene-receptor antagonists, such as zafirlukast, may pro-
vide a significant alternative for dealing with poor
compliance and may ultimately improve asthma outcomes
(13,15). Orally administered zafirlukast has been shown to
reduce asthma symptoms and rescue use of bronchodila-
tors, improve lung function, improve quality of life
measurements, and decrease exacerbations when adminis-
tered twice a day (16–18). Furthermore, early evaluation of
patient compliance with zafirlukast therapy is promising. In
a study evaluating the long-term ecacy and safety of
zafirlukast, the compliance rate based on tablet counts was
94?5% at 52 weeks of treatment (19). Because tablet count
methods tend to overestimate compliance and do not
provide insight into drug use patterns, a pilot compliance
study, as reported here, was conducted with zafirlukast to
measure long-term compliance electronically and to com-
pare results with compliance calculated from tablet counts
for individual patients.
Methods and materials
PATIENTS
Male and female patients, 18–55 years of age, with a history
of asthma were sought for enrollment. Asthma history was
defined as previous patient response to standard asthma
treatment, episodic wheezing, or changes in lung function
over short periods of time. Patients who were using any
asthma medication, other than as-needed, short-acting b2-
agonists, were excluded from screening. Patients eligible to
receive trial treatment were those who, during the screening
period, had a 1-sec forced expiratory volume (FEV1) of
60% predicted; a15% improvement in peak expiratory
flow (PEF) or FEV1 after a 400-mg inhaled dose of
salbutamol; and symptomatic reversible airways obstruc-
tion that required additional controller asthma therapy, as
determined from screening diary cards.
Major reasons for exclusion included other significant
respiratory disease; recent hospitalization for asthma;
recent history of respiratory tract infection; seasonal
asthma; use of corticosteroids, cromones, or long-acting2-agonists in the weeks that preceded the trial; recent
participation in another clinical trial; and any clinically
significant medical condition that would interfere with trial
assessments or increase the patient’s risk.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the desig-
nated ethics committee at each centre. Written informed
consent was obtained after patients received a description
of the trial’s purpose and procedures. The informed consent
form mentioned that compliance, pulmonary function and
safety would be measured. Patients, however, were not
informed that compliance was under electronic surveillance
so as not to introduce an unacceptable bias in favour of
compliance (5). Standards of ethics were considered
maintained because patients were not subjected to addi-
tional risk, and patients’ rights and welfare were neither
violated nor aected.
STUDY DESIGN
This study was a 15-week, open-label, non-comparative
trial and the first to define compliance for zafirlukast
according to a dosing schedule. An initial screening period
of 2–3 weeks was followed by a 12-week treatment period
during which patients took zafirlukast 20 mg twice a day.
The purpose of the screening period was to find out if
patients had reversible airway obstruction that made them
suitable candidates for a stepwise increase in asthma
therapy. At the start of the treatment period, each patient
received 56 tablets of zafirlukast, enough for 3 weeks, with
one week’s supply to spare. Tablets were dispensed in
screw-top bottles fitted with a TrackCapTM medication
event monitoring system (MEMS) device (APREX Cor-
poration, Fremont, California, U.S.A.), that recorded the
date and time on each occasion when the cap was removed
and replaced. Patients were scheduled to return to the clinic
every 3 weeks for four more visits. At three of those visits,
patients exchanged bottles with unused tablets for newly
stocked bottles of 56 tablets; at the fourth visit, no new
supplies were issued.
The following dosing instructions were on the bottle and
outer cartons: ‘Take one tablet in the morning and one
tablet in the evening approximately 12 h apart. Do not take
the tablets at mealtimes.’ Patients were also instructed to
remove one tablet at a time and immediately replace the cap
because the tablets were sensitive to moisture. A desiccant
capsule, found in each bottle, visually reinforced the need to
replace the cap as directed. Patients were not required to
keep asthma diaries during the treatment period, and tablet
counts were neither assessed nor discussed in the patient’s
presence.
Each removal of the TrackCapTM was presumed to
indicate a single medication-use event. The device, however,
was programmed to recognize, but not accumulate, multi-
ple openings that occurred within 1 min of each other. If
the cap was left o for 15 min or more, the device recorded
one additional event. To prevent extraneous results, study
personnel were asked not to open the bottles before, during,
or after the study period.
854 K. F. CHUNG AND I. NAYAPatients were assessed at each clinic visit for lung
function [peak expiratory flow rate (PEF) and forced
expiratory volume in 1 sec (FEV1)] and adverse events.
Patients who withdrew underwent a complete physical
examination and a standard battery of laboratory and
pulmonary function tests at the time of withdrawal.
ANALYSISPercent TrackCapTM compliance was defined as follows:
% Compliance  100Number of TrackCap
TM events
Number of prescribed tablets
Compliance also was estimated from returned tablet counts, with percent compliance defined as:
% Compliance  100Number of dispensed tablets minus number of returned tablets
Number of prescribed tablets
TrackCapTM adherence was the degree to which patients followed dosing instructions precisely on a daily basis and was
defined as follows:
% Adherence  100Number of days with 2 TrackCap
TM events at least 8 h apart
Total number of days0 dosingTABLE 1. Demographic and clinical characteristics at entry
Characteristic (n=57)
Men/Women, n (%) 32 (56)/25 (44)
Age (years)
Mean (SD) 29 (9)
Range 18 to 55
Race, n
Caucasian/Asian 56/1
Mean % predicted FEV1 (SD) 77% (13)
Mean % FEV1 reversibility (SD) 26% (10)
Mean % PEF reversibility (SD) 20% (7)
Mean years with asthma (SD) 14 (10)
SD: standard deviation; FEV1: forced expiratory volume in
1 sec; PEF: peak expiratory flow.In addition, days were classified as days with two events
58 h apart (insucient interval adherence), days with only
one event (undercompliance), days with no event (no
compliance), and days with more than two events (over-
compliance). A day was defined as the 24-h period from
03?00 h on one day to 02?59 h on the next day. For each
category, the total number of days that a patient was
classified as such was calculated and expressed as a
percentage of the total number of days the patient was on
trial treatment.
Summaries of compliance and adherence were based on
data from patients who completed the entire 12 weeks of
treatment. In the evaluation of TrackCapTM data, only
events that were recorded during the treatment period were
considered, i.e., events that occurred before tablets were
dispensed or after containers were returned were dis-
counted. Initial plans to calculate 95% confidence intervals
for mean compliance and adherence were not applicable
after a test for normality (Shapiro–Wilk test) showed that
compliance and adherence data were not normally dis-
tributed. Therefore, both means and medians are reported.
To evaluate consistency of compliance over time, as well
as pattern of drug use relative to clinic visits, mean
compliance was calculated weekly for all patients for whom
data were available during that week. Patients who with-
drew were included in this analysis because they were more
likely to represent a non-compliant population.
Results
DEMOGRAPHY
A total of 75 patients from five sites underwent screening
for possible study entry; of those, 57 met entry criteria and
began treatment with zafirlukast. The study population,32 men and 25 women, had a mean age of 29 years, and
they had a mixed socioeconomic background. At entry,
mean % predicted FEV1 was 77%, and duration of asthma
ranged from 10 months to 42 years. Additional patient
characteristics are summarized in Table 1.
Of the 57 patients who received zafirlukast, 47 completed
the prescribed 12 weeks of treatment. Among patients
withdrawn were three who did not comply with theprotocol, two who did not return for follow-up visits, two
who withdrew consent, one who had an adverse event (mild
headache), and one who was erroneously enrolled.
TRACKCAPTM ADHERENCE AND
COMPLIANCE
As calculated from TrackCapTM events, median adherence
was 71% (mean, 64%) of the days of dosing (lower quartile,
51%; upper quartile, 81%), and median compliance was
89% (mean, 80%) (Tables 2 and 3). The distribution of
percent adherence and compliance values are shown in
Figs 1 and 2. Sixty-six percent of the patients had good
compliance according to TrackCapTM measurements (took
 80% of the prescribed doses). On days when patients
took exactly two tablets, the mean time between doses was
12 h 34 min (range, 17 min to 21 h 1 min), with tablets
TABLE 2. Summary data for compliance, n=47
Mean (SD)
%
Lower quartile
%
Median
%
Upper quartile
%
TrackCapTM compliance* 80 (24) 74 89 96
Tablet count compliance{ 89 (11) 84 92 96
*Number of events divided by number of prescribed tablets6100.{ Number of dispensed tablets minus returned tablets
divided by the number of prescribed tablets6100.
TABLE 3. Summary data for adherence, n=47
Mean (SD)
% of days
Lower quartile
% of days
Median
% of days
Upper quartile
% of days
Full adherence (2 events  8 h apart) 64 (26) 51 71 81
Insucient interval adherence (2 events 58 h apart) 3 (4) 1 2 4
Undercompliance (1 event/day) 20 (14) 10 19 25
No compliance (0 events/day) 10 (21) 0 1 8
Overcompliance (>2 events/day) 2 (2) 0 2 4
FIG. 1. Distribution of percentages of days with full
adherence to zafirlukast therapy as determined by
TrackCapTM.
FIG. 2. Distribution of percentages of prescribed doses of
zafirlukast taken (compliance) as determined by
TrackCapTM.
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treatment days, 2624).
Patients had one TrackCapTM event on a median of 19% of
the days, and had insucient interval adherence on a median
of 2% days (Table 3). The median percent of days when
patients took no tablets was 1%. Patients were over-
compliant (>two tablets day71) on a median of 2% of days.
COMPLIANCE ESTIMATED FROM TABLET
COUNT
On the basis of tablet counts, median compliance was 92%
(mean, 89%), which was slightly higher than compliance
calculated from TrackCapTM events (Table 2). For 39 of 47
patients (83%), the dierences between values derived fromthe two methods were marginal (within+15%), suggesting
that patients removed multiple tablets at a time infrequently
(Fig. 3). For eight patients, however, compliance based on
tablet counts was greater by 20% or more, indicating that
these patients did not remove trial medication as instructed.
The pattern of TrackCapTM events suggested that one patient
removed up to a week’s supply of tablets at each opening.
Two patients (4%), recorded multiple events (up to 37 bottle
openings within a 2-min period) before clinic visits, which
suggested that these patients suspected compliance monitor-
ing and attempted to conceal poor compliance.
WEEKLY COMPLIANCE
Three patients did not return the TrackCapTM device, but all
other patients provided at least a week of TrackCapTM event
FIG. 3. TrackCapTM observed compliance. vs. tablet count
compliance with zafirlukast therapy.
FIG. 4. Weekly median TrackCapTM compliance with
zafirlukast therapy and weekly percentages of patients
with TrackCapTM compliance  80% (numbers of patients
in parentheses).
856 K. F. CHUNG AND I. NAYAdata. The weekly mean data are summarized in Fig. 4. The
mean level of compliance over time remained consistently
high from week 1 through week 12 of treatment. Clinic
visits did not appear to have a great eect on compliance.
OTHER ASSESSMENTS
Zafirlukast was well tolerated throughout the trial. The
most frequently reported adverse events were non-treat-
ment-related infections (primarily respiratory infections) in
11 patients (19%) and headache in 10 patients (18%). Mean
FEV1 remained unchanged but mean PEF increased 8%
from the end of screening.
Discussion
This was the first study to evaluate compliance with an oral
asthma medication using a medication event monitoring
system. As assessed by the electronic TrackCapTM device,
compliance with twice-daily oral zafirlukast was high
(median, 89%). These results confirm the high levels of
compliance reported for zafirlukast in clinical trials, as
estimated from returned-tablet counts (19). Also, 66% of
patients achieved a good level of compliance. Importantly,
through 12 weeks of treatment, levels of compliance
remained consistently high.
Although median adherence in this study was not as high
as median compliance, it was also high at 71%. The
dierence between these assessments was primarily asso-
ciated with days when one tablet was taken. Days of no
compliance accounted for only a median of 1% of the days.
Overall, then, patients took zafirlukast according to dosing
instructions for most of the 12-week treatment period; on
most other days, patients took at least half the daily dose.
Adherence with zafirlukast was more than five times greater
than adherence measured electronically (14%) for a four-
times-daily regimen of inhaled nedocromil (4).Not surprising was the fact that mean compliance
calculated from the returned-tablet counts (89%) was
greater than that calculated from TrackCapTM events
(80%). This phenomenon of overestimation of compliance
by tablet count may be attributed to accidental loss of
medication, removal of multiple tablets at bottle openings,
or deliberate disposal of tablets to disguise underusage. A
similar corollary is documented for inhaled asthma
medication in that residual MDI canister weights and daily
use records also overestimate compliance (2,4,20,21). In this
study, the dierence in compliance as calculated by the
TrackCapTM and tablet-count methods was minor and
mostly could be attributed to eight patients who clearly did
not follow specific dosing instructions. However, just as it
was possible that some patients may have removed tablets
and not taken them, it was possible that some patients,
despite their failure to comply with instructions regarding
tablet removal, still took the medication according to the
prescribed regimen.
The overall conclusions that can be drawn from this
study are limited in that, without a comparator, we could
not assess how well these patients might have complied with
other asthma treatments. We cannot exclude the possibility
that these patients were simply a more compliant group.
However, mean compliance according to tablet counts was
94?5% in a long-term zafirlukast trial in North America
(19), which suggests that the patients studied in this trial did
not represent a highly compliant group. The patients
included in our study were not previously following a
regular regimen of asthma therapy. It is unclear if patients
who were previously on a regular regimen might have had a
higher compliance. A compliance rate of 79%, which was
similar to that measured in our study, was reported for
twice-daily theophylline when medical records from an
health maintenance organization population were retro-
spectively compared with prescription refill records (12).
The theophylline study had the disadvantage of not being
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not introducing the potential for bias related to patient
selection and study participation. In our study, compliance
rates may have been influenced because patients knew they
were in a trial and had obligations to return at set intervals.
In several compliance studies that required follow-up visits,
patients demonstrated a variety of behaviours related to
drug administration, e.g., increasing medication use around
clinic visits, taking only half the recommended dose for the
trial duration, or taking medication as directed for self-
determined blocks of time (5,22,23). None of these
behaviours occurred in this trial, which lends credibility
to the rate of compliance and adherence achieved. Patterns
of multiple-grouped TrackCapTM events did suggest that
some patients realized the purpose of the device.
Among the various direct and indirect methods currently
used to assess compliance, none does so perfectly (14).
Direct methods are ultimately inconvenient, and indirect
methods, with inference of drug use, are problematic in
determining the extent of full compliance and accounting
for patient behaviours. The precedence for use of electronic
methods was previously established in studies that evalu-
ated compliance in patients with hypertension (24) and
epilepsy (25). In addition to achieving adherence rates
similar to the rate achieved in this study, those studies also
revealed that adherence (full compliance) was inversely
proportional to frequency of dosing.
Eorts to prevent a bias in favour of compliance in this
study—not apprising patients of the nature of the
TrackCapTM focusing on lung function and safety at clinic
visits; and not requiring use of diary cards during the
treatment period—were considered to be both necessary to
approximate real-world compliance and within the scope of
acceptable clinical practice. The value of this study will be
reflected in future double-blind, crossover studies that
compare electronically assessed compliance among dierent
forms of asthma treatments and that do not emphasize the
compliance objective to patients.
Despite the proven benefits of inhaled steroids, patients
continue, for numerous reasons, to use them inappropri-
ately and inconsistently, thus not achieving the true benefit
(20,26). That patients with asthma prefer oral treatment
like zafirlukast to inhaled treatment like beclomethasone
dipropionate (27) is not surprising given reported compli-
ance rates. Importantly, such preferences are likely to aect
how physicians and other healthcare providers ultimately
approach treatment.
In conclusion, data from this study show that it is
possible to assess adherence and compliance with an oral
asthma medication using a medication event monitoring
system like TrackCapTM. These results show that compli-
ance with and adherence to a treatment of an oral, twice-
daily, maintenance asthma medication, such as zafirlukast,
is high.
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